Funding benchmark · last 12 months
From 34 Series B rounds announced in Biotech over the last twelve months, each read from a named source. Half of them raised between $32M and $125M.
34 rounds counted · recounted nightly
The trend
From $55M in 2025 Q1 to $43M in 2026 Q3. Quarters with fewer than five rounds are left blank.
Who leads
The firms that led the most Series B rounds in Biotech this year.
Recent examples
Prolific Machines22 Oct 2026 · Atoms & Bits$50M-20%
Matchpoint Therapeutics7 Oct 2026 · Norwest Venture Partners$150M+140%
AnaCardio1 Oct 2026 · Ljungström family office$71M+13%
Biossil28 Sept 2026 · OpenAI Startup Fund$153M+145%
Holiferm24 Sept 2026 · Not named$16M-75%
Evvy15 Sept 2026 · Catalio Capital Management$40M-36%
NovaGo Therapeutics2 Sept 2026 · Pureos Bioventures$30M-52%
Qureight29 Jul 2026 · Molten Ventures$20M-68%They come from announced rounds. Large rounds are almost always announced and many small ones never are, so the true typical round is probably a little smaller than shown, most of all at pre-seed and seed. Every round behind them is in the record with its source. How we read rounds.
Other stages in Biotech
See who leads rounds like yours,
and check your raise before you pitch.
The median is $63M, from 34 Series B rounds announced in Biotech in the last twelve months. Half of them raised between $32M and $125M; one in ten raised more than $146M.
Rounds announced in the last twelve months with a stated amount and stage, each read from a named article or filing. A page is only published where at least 30 rounds stand behind it.
Towards larger rounds, yes. Big rounds are announced; many small ones never are. So the true typical round is probably a little smaller than the figure here, especially at pre-seed and seed.
The figures are recounted from the record every night, as new rounds are read.